AIM: To explore dendritic cells (DCs) multiple functions in immune modulation. METHODS: We used bone-marrow derived dendritic cells from BALB/c mice pulsed with pseudo particles from the hepatitis C virus to vaccinate naive BALB/c mice. Hepatitis C virus (HCV) pseudo particles consist of the genotype 1b derived envelope proteins E1 and E2, covering a non-HCV core structure. Thus, not a single epitope, but the whole "viral surface" induces immunogenicity. For vaccination, mature and activated DC were injected subcutaneously twice. RESULTS: Humoral and cellular immune responses measured by enzyme-linked immunosorbent assay and interferon-gamma enzyme-linked immunosorbent spot test showed antibody production as well as T-cells directed against HCV. Furthermore, T-cell responses confirmed two highly immunogenic regions in E1 and E2 outside the hypervariable region 1. CONCLUSION: Our results indicate dendritic cells as a promising vaccination model for HCV infection that should be evaluated further.
AIM: To explore dendritic cells (DCs) multiple functions in immune modulation. METHODS: We used bone-marrow derived dendritic cells from BALB/c mice pulsed with pseudo particles from the hepatitis C virus to vaccinate naive BALB/c mice. Hepatitis C virus (HCV) pseudo particles consist of the genotype 1b derived envelope proteins E1 and E2, covering a non-HCV core structure. Thus, not a single epitope, but the whole "viral surface" induces immunogenicity. For vaccination, mature and activated DC were injected subcutaneously twice. RESULTS: Humoral and cellular immune responses measured by enzyme-linked immunosorbent assay and interferon-gamma enzyme-linked immunosorbent spot test showed antibody production as well as T-cells directed against HCV. Furthermore, T-cell responses confirmed two highly immunogenic regions in E1 and E2 outside the hypervariable region 1. CONCLUSION: Our results indicate dendritic cells as a promising vaccination model for HCV infection that should be evaluated further.
Authors: H M Diepolder; J T Gerlach; R Zachoval; R M Hoffmann; M C Jung; E A Wierenga; S Scholz; T Santantonio; M Houghton; S Southwood; A Sette; G R Pape Journal: J Virol Date: 1997-08 Impact factor: 5.103
Authors: I Nakano; G Maertens; M E Major; L Vitvitski; J Dubuisson; A Fournillier; G De Martynoff; C Trepo; G Inchauspe Journal: J Virol Date: 1997-09 Impact factor: 5.103
Authors: P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell Journal: Proc Natl Acad Sci U S A Date: 1996-12-24 Impact factor: 11.205
Authors: D Rosa; S Campagnoli; C Moretto; E Guenzi; L Cousens; M Chin; C Dong; A J Weiner; J Y Lau; Q L Choo; D Chien; P Pileri; M Houghton; S Abrignani Journal: Proc Natl Acad Sci U S A Date: 1996-03-05 Impact factor: 11.205
Authors: C Oseroff; A Sette; P Wentworth; E Celis; A Maewal; C Dahlberg; J Fikes; R T Kubo; R W Chesnut; H M Grey; J Alexander Journal: Vaccine Date: 1998-05 Impact factor: 3.641